Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children
PLoS ONE, Volume 4, No. 10, Article e7549, Year 2009
Notification
URL copied to clipboard!
Description
Background: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult volunteers in Burkina Faso confirmed that the vaccine was safe. The aim of this study was to assess the safety and immunogenicity of this vaccine candidate in children aged 12-24 months living in malaria endemic area of Burkina Faso. Methods: The study was a double-blind, randomized, controlled, dose escalation phase Ib trial, designed to assess the safety, reactogenicity and immunogenicity of three doses of either 15 or 30 μg of MSP3-LSP adsorbed on aluminum hydroxide in 45 children 12 to 24 months of age randomized into three equal groups. Each group received 3 vaccine doses (on days 0, 28 and 56) of either 15 μg of MSP3-LSP, 30 μg of MSP3-LSP or of the Engerix B hepatitis B vaccine. Children were visited at home daily for the 6 days following each vaccination to solicit symptoms which might be related to vaccination. Serious adverse events occurring during the study period (1 year) were recorded. Antibody responses to MSP3-LSP were measured on days 0, 28, 56 and 84. Results: All 45 enrolled children received three MSP3 vaccine doses. No serious adverse events were reported. Most of the adverse events reported were mild to moderate in severity. The only reported local symptoms with grade 3 severity were swelling and induration, with an apparently dose related response. All grade 3 adverse events resolved without any sequelae. Both MSP3 doses regimens were able to elicit high levels of anti-MSP3 specific IgG1 and IgG3 antibodies in the volunteers with very little or no increase in IgG2, IgG4 and IgM classes: i.e. vaccination induced predominantly the isotypes involved in the monocyte-dependent mechanism of P. falciparum parasite-killing. Conclusion: Our results support the promise of MSP3-LSP as a malaria vaccine candidate, both in terms of tolerability and of immunogenicity. Further assessment of the efficacy of this vaccine is recommended. © 2009 Sirima et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC2764341/bin/pone.0007549.s001.rtf
https://efashare.b-cdn.net/share/pmc/articles/PMC2764341/bin/pone.0007549.s002.rtf
https://efashare.b-cdn.net/share/pmc/articles/PMC2764341/bin/pone.0007549.s003.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC2764341/bin/pone.0007549.s004.rtf
Authors & Co-Authors
Sirima, Sodiomon Bienvenu
Unknown Affiliation
Tiono, Alfred Bewendtaoré
Unknown Affiliation
Ouédraogo, Alphonse Risgou
Unknown Affiliation
Diarra, Amidou
Unknown Affiliation
Ouédraogo, André Lin
Unknown Affiliation
Yaro, Jean Baptiste
Unknown Affiliation
Ouédraogo, Espérance B.
Unknown Affiliation
Gansané, Adama
Unknown Affiliation
Bougouma, Edith Christiane
Unknown Affiliation
Konaté, Amadou Tidiani
Unknown Affiliation
Kabore, Youssouf
Unknown Affiliation
Traoré, Abdoulaye Mamadou
Unknown Affiliation
Roma, Chilengi
Unknown Affiliation
Soulama, Issiaka
Unknown Affiliation
Luty, A. J.F.
Unknown Affiliation
Cousens, Simon Nicholas
Unknown Affiliation
Nèbiè, Issa O.
Unknown Affiliation
Statistics
Citations: 64
Authors: 17
Affiliations: 6
Identifiers
Doi:
10.1371/journal.pone.0007549
e-ISSN:
19326203
Research Areas
Disability
Infectious Diseases
Maternal And Child Health
Study Locations
Burkina Faso